ALK and non-small cell lung carcinoma: Of note, the phase 3 IMpower150 study showed that atezolizumab plus bevacizumab plus chemotherapy significantly improved PFS (8.3 months vs. 6.8 months) and OS (19.2 months vs. 14.7 months) in patients with metastatic non-squamous NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status [70].